Compare Kimberly Clark Corp (KMB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Kimberly Clark Corp trades at $108.01 (market cap $36.01B), while State Street SPDR S&P Biotech ETF trades at $151.8. The key difference: Kimberly Clark Corp pays a 4.72% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Kimberly Clark Corp nearer its low. Which is the better fit depends on your goals.
| KMB | XBI | |
|---|---|---|
Market Cap | $36.01B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $136.77 | $164.28 |
52-Week Low | $93.05 | $85.16 |
Enterprise Value | $42.55B | — |
Dividend Yield | 4.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $108.43, up 0.07% on the day, with a neutral technical signal and bullish moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.97 exceeding the $1.93 estimate. Revenue declined to $16.45B in 2025, but net income margin remains strong at 12.8%. Recent news highlights KMB's innovation strategy and its status as a Dividend King, with a 4.5% yield attracting income investors.
KMB offers stable income with a high dividend yield and solid fundamentals, but faces revenue pressure and competitive risks. Analyst consensus is a $115.33 price target with a hold-heavy rating. Key risks include consumer sentiment impacts and input cost inflation, while the pending Kenvue merger provides growth potential.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
